Literature DB >> 3617011

Inhibition of the tissue factor-factor VII complex: involvement of factor Xa and lipoproteins.

A R Hubbard, C A Jennings.   

Abstract

Inhibition of the procoagulant activity of a tissue factor-Factor VII (TF-FVII) complex by Al(OH)3-adsorbed plasma (AP) was found to require the presence of Factor Xa (FXa). Inhibitory activity seems to be generated through the interaction of FXa with a component in AP rather than with the TF-FVII complex. Quantitation of inhibitor activity was carried out using an amidolytic assay for TF-FVII activity. Incubation of AP with various antisera demonstrated that the inhibition was mainly associated with the presence of apolipoprotein B (apo B) rather than alpha 2-macroglobulin or antithrombin III. Purified lipoprotein-rich fractions prepared from AP, using density gradient ultracentrifugation, all contained some inhibitory activity. Incubation with anti-apo B greatly reduced the inhibitor in the very low density lipoprotein (VLDL)- and low density lipoprotein (LDL)-rich fractions but had essentially no effect on inhibition by the high density lipoprotein (HDL) fraction, which was rich in apo A. The inhibitory activity of AP was 60% that of normal plasma and this correlated well with the relative apo A and apo B concentrations. It is proposed that inhibition requires the interaction of FXa with plasma lipoproteins or associated components and that the product of this interaction is then able to bind to and inhibit the TF-FVII complex.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3617011     DOI: 10.1016/0049-3848(87)90154-x

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  8 in total

1.  Clotting for the Clinician: An Overview of Thrombosis and Antithrombotic Therapy.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

2.  Hemophilia as a defect of the tissue factor pathway of blood coagulation: effect of factors VIII and IX on factor X activation in a continuous-flow reactor.

Authors:  D Repke; C H Gemmell; A Guha; V T Turitto; G J Broze; Y Nemerson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

3.  Endogenous phosphorylation of the lipoprotein-associated coagulation inhibitor at serine-2.

Authors:  T J Girard; D McCourt; W F Novotny; L A MacPhail; K M Likert; G J Broze
Journal:  Biochem J       Date:  1990-09-15       Impact factor: 3.857

Review 4.  Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute respiratory distress syndrome.

Authors:  Sara C Sebag; Julie A Bastarache; Lorraine B Ware
Journal:  Curr Pharm Biotechnol       Date:  2011-09       Impact factor: 2.837

5.  The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor.

Authors:  I Warshawsky; G J Broze; A L Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

Review 6.  Biology of tissue factor pathway inhibitor.

Authors:  Jeremy P Wood; Paul E R Ellery; Susan A Maroney; Alan E Mast
Journal:  Blood       Date:  2014-03-11       Impact factor: 22.113

Review 7.  Tissue factor pathway inhibitor: structure-function.

Authors:  George J Broze; Thomas J Girard
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

8.  Studies on Tissue Factor Pathway Inhibitor Antigen Release by Bovine, Ovine and Porcine Heparins Following Intravenous Administration to Non-Human Primates.

Authors:  Ahmed Kouta; Debra Hoppensteadt; Emily Bontekoe; Walter Jeske; Richard Duff; Lee Cera; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.